Buying out Immunogen Inc. in a whopper cash deal valued at about $10.1 billion, Abbvie Inc. has major plans for an expanded label on the antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx), already approved for treating platinum-resistant ovarian cancer. Read More
Five months since Eli Lilly and Co.’s $2.4 billion buyout of Dice Therapeutics Inc. and its Delscape platform for oral small-molecule inhibitors of protein-protein interactions, Lilly rolled the dice again for novel PPI targets by partnering with Japanese biotech Prism Biolab Co. Ltd. Read More
After five years and 350,000 hours of DNA sequencing, the UK Biobank has opened up access Nov. 30 to the whole genome sequences of half a million people who volunteered to give samples 15 years ago. Read More
Patients with end-stage pancreatic ductal adenocarcinoma achieved unprecedented survival rates after being treated with the Engeneic dream vector nanocells, with 88% of patients doubling the historical survival rates, Engeneic Ltd. co-CEO Jennifer MacDiarmid told BioWorld.Read More
For biopharma, the 2023 post-pandemic reality check has been harsh, replete with sagging stock prices, bankruptcy filings and restructurings, as well as IPOs at their lowest levels in a decade. The good news, according to a handful of industry experts, is that it could be coming to an end, possibly as early as 2024. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelyrin, Fortrea, Intas, Johnson & Johnson, Obseva, Roche, Samsung Bioepis, Shape, Sanofi, Teva, Tiziana. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arcutis, Biocardia, Biocryst, Italfarmaco, Karuna, KSQ, Oxford, Pasithea, Projenx, Uniqure, Valo. Read More
